P16 deletion and mutation analysis in human brain tumors

Journal of Neuro-Oncology

Volumn 31, Issue 1-2, 1997, Pages 17-23

  Barker, Fred G ^a   Chen, Pengchin ^a   Furman, Felix ^a   Aldape, Ken D ^a   Edwards, Michael S B ^a   Israel, Mark A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Brain Tumor Research Center   (United States)

Author keywords

Cyclin dependent kinase inhibitors; Glioblastoma; Malignant glioma; Medulloblastoma; Meningioma; P16

Indexed keywords

PROTEIN P16;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; GENE STRUCTURE; GLIOMA; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MEDULLOBLASTOMA; MENINGIOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE; SINGLE STRAND CONFORMATION POLYMORPHISM;

CARRIER PROTEINS; CEREBELLAR NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; ENZYME INHIBITORS; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; MEDULLOBLASTOMA; MENINGEAL NEOPLASMS; MENINGIOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0031039957     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005768910871     Document Type: Article

References (33)

1. Bello MJ, de Campos JM, Vaquero J, Kusak ME, Sarasa JL, Pestana A, Rey JA: Molecular and cytogenetic analysis of chromosome 9 deletions in 75 malignant gliomas. Genes Chromosom Cancer 9: 33-41, 1994
2. Coleman A, Fountain JW, Nobori T, Olopade OI, Robertson G, Housman DE, Lugo TG: Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res 54: 344-348, 1994
3. James CD, He J, Collins VP, Allalunis-Turner MJ, Day RS 3rd: Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group. Cancer Res 53: 3674-3676, 1993
4. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature 366: 704-707, 1993
5. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994
6. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994
7. Nicholas MK, Stadler WM, Olopade O: Detection of loss of allelic heterozygosity on human chromosome 9p in gliomas (Abstract). Ann Neurol 36: 328, 1994
8. Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN, Gusella JF, Ramesh V: Mutational analysis of CDKN2 (MTS1/p16-ink4) in human breast carcinomas. Cancer Res 54: 5262-5264, 1994
9. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, Huebner K: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 54: 5269-5272, 1994
10. Zhang S-Y, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54: 5050-5053, 1994
11. Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA: Constitutional p53 mutations associated with brain tu-mors in young adults. Cancer Genet Cytogenet 82: 106-115, 1995
12. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M: Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocyto-mas. Cancer Res 55: 20-23, 1995
13. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS 3rd, James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807, 1994
14. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr., Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Na-ture Genetics 8: 15-21, 1994
15. Ueki K, Rubio M-P, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN: MTS1/ CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Molec Genet 3: 1841-1845, 1994
16. Kamb A: Cell-cycle regulators and cancer. Trends Genet 11: 136-140, 1995
17. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang H-JS: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354, 1995
18. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumors with 9p loss (letter). Science 265: 415-417, 1994
19. Giani C, Finocchiaro G: Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 54: 6338-6339, 1994
20. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994
21. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994
22. Moulton T, Samara G, Chung W-Y, Yuan L, Desai R, Sisti M, Bruce J, Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146: 613-619, 1995
23. Rao LS, Newcomb EW: Infrequent p16/CDKN2 gene mutations in human primary astrocytic and non-astrocytic brain tumors. Proc AACR 36: 581, 1995 (abstract)
24. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Huang H-JS: Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res 55: 1941-1945, 1995
25. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10: 351-353, 1995
26. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ: Absence of p16-INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375-3378, 1994
27. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505-509, 1995
28. Aagaard L, Lukas J, Bartkova J, Kjerulff AA, Strauss M, Bartek J: Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur on distinct sub-sets of human cancer cell lines. Int J Cancer 61: 115-120, 1995
29. Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, Johnson BE: Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst 87: 756-761, 1995
30. Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbenderr F, Xu H-J, Benedict WF, Yandell DW, Louis DN: The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 36: 714-721, 1994
31. Hamel W, Westphal M, Shepard HM: Loss in expression of the retinoblastoma gene product in human gliomas is associated with advanced disease. J Neurooncol 16: 159-165, 1993
32. Venter DJ, Bevan KL, Ludwig RL, Riley TE, Jat PS, Thomas DG, Noble MD: Retinoblastoma gene deletions in human glioblastomas. Oncogene 6: 445-448, 1991
33. Raffel C, Ueki K, Harsh GR 4th, Louis DN: The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor. Neurosurgery 36: 971-975, 1995